Of particular interest in the HNSCC diagnostic, clinical prognosis and/or risk assessment could be the methylation of CDH1, which was also previously described as a possible biomarker for the early detection and treatment of HNSCC [32,36,46,47]. The gene discussed is CDH1; the disease is head and neck squamous cell carcinoma.